The Chinese drug administration denied the application of Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Sinopharm Zhijun (Shenzhen) Pharmaceutical, to market fosfomycin tromethamine granules, according to a Shanghai Stock Exchange disclosure on Friday.
The application did not meet relevant requirements for drug registration, the pharmaceutical company said.
The drug was developed to treat infections caused by sensitive Escherichia coli, Enterococcus faecalis, Klebsiella pneumoniae, Citrobacter, Enterobacter, and Proteus mirabilis, such as acute simple urinary tract infection.
The company, which spent 11.5 million yuan into the drug's research and development, said it will re-initiate the research, application and registration work for the drug.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。